1. |
Greten TF, Korangy F, Manns MP, et al. Molecular therapy for the treatment of hepatocellular carcinoma. Br J Cancer, 2009, 100(1): 19-23.
|
2. |
Yan T, Wunder JS, Gokgoz N, et al. COPS3 amplification and clinical outcome in osteosarcoma. Cancer, 2007, 109(9): 1870-1876.
|
3. |
Whittaker S, Marais R, Zhu AX. The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene, 2010, 29(36): 4989-5005.
|
4. |
Shimizu M, Saitoh Y, Itoh H. Immunohistochemical staining of Ha-ras oncogene product in normal, benign, and malignant human pancreatic tissues. Hum Pathol, 1990, 21(6): 607-612.
|
5. |
Kato JY, Yoneda-Kato N. Mammalian COP9 signalosome. Genes Cells, 2009, 14(11): 1209-1225.
|
6. |
Zhao R, Yeung SC, Chen J, et al. Subunit 6 of the COP9 signalosome promotes tumorigenesis in mice through stabilization of MDM2 and is upregulated in human cancers. J Clin Invest, 2011, 121(3): 851-865.
|
7. |
Miliani de Marval PL, Zhang Y. The RP-Mdm2-p53 pathway and tumorigenesis. Oncotarget, 2011, 2(3): 234-238.
|
8. |
Manfredi JJ. The Mdm2-p53 relationship evolves: Mdm2 swings both ways as an oncogene and a tumor suppressor. Genes Dev, 2010, 24(15): 1580-1589.
|
9. |
Yan T, Tang G, Ren T, et al. RNAi-mediated COPS3 gene silencing inhibits metastasis of osteogenic sarcoma cells. Cancer Gene Ther, 2011, 18(6): 450-456.
|
10. |
Henriksen J, Aagesen TH, Maelandsmo GM, et al. Amplification and overexpression of COPS3 in osteosarcomas potentially target TP53 for proteasome-mediated degradation. Oncogene, 2003, 22(34): 5358-5361.
|
11. |
Yan T, Wunder JS, Gokgoz N, et al. COPS3 amplification and clinical outcome in osteosarcoma. Cancer, 2007, 109(9): 1870-1876.
|